Know Cancer

forgot password

The Added Value of SPECT/CT in the Evaluation of Endocrine and Neuroendocrine Tumors

18 Years
Not Enrolling
Endocrine and Neuroendocrine Tumors

Thank you

Trial Information

The Added Value of SPECT/CT in the Evaluation of Endocrine and Neuroendocrine Tumors

The value of fusion of functional and anatomical data has been described using several
fusion techniques for various nuclear medicine procedures and morphologic imaging modalities
(SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over
the data obtained using separately performed NM study and conventional anatomic imaging as
CT. We hypothesize that more accurate localization of the radio-isotope activity on NM
images will improve diagnostic accuracy and will have an impact on patient management:

Improved accuracy of NM study will improve tumor localization, the evaluation of the extent
of disease and the post therapy follow up.

It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the
need for more invasive procedures. It can also guide invasive procedures and
radiation-therapy planning, thus improving therapy results and avoiding unnecessary
treatment-related side effects.

Inclusion Criteria:

- Patient referred for NM scintigraphy to assess the presence of endocrine or
neuroendocrine tumors.

- Patient signed informed consent

Exclusion Criteria:

- The study will not be performed in pregnant or lactating women.

- Patient will not be able or willing to tolerate the scan until its completion.

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

The impact of imaging modality on patient management

Safety Issue:


Principal Investigator

Zohar Keidar, MD,PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Rambam Health Care Campus


Israel: Israeli Health Ministry Pharmaceutical Administration

Study ID:




Start Date:

January 2002

Completion Date:

January 2006

Related Keywords:

  • Endocrine and Neuroendocrine Tumors
  • Neuroendocrine Tumors